The Power of PoP

POP BIO uses two patented porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in oncology and infectious disease

1.) The Spontaneous Nanoliposome Antigen Particleization (SNAP) platform enables the rapid development of highly immunogenic vaccines

2.) Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors expose to specific laser light.

Learn more about our technologies

Latest News

September 19, 2022

POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
February 4, 2022

POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
December 13, 2021

How to freeze-dry a potential COVID-19 vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.